The global immune-mediated inflammatory disease treatment market is anticipated to grow at a CAGR of over 6% during the forecast period. Immune-mediated inflammatory disease treatment has been improved significantly over the past years due to the development of a series of targeted biological therapies and novel therapies in the market. Currently, quite a lot of research is going on in the field regarding the treatment of immune-mediated disease. In addition, new drugs and treatment options are entering the market, which is fuelling the growth of the global immune-mediated inflammatory disease treatment market. For instance, in August 2019, the US FDA approved upadacitinib (Rinvoq), an oral medication for adults with moderate to severe rheumatoid arthritis that is not being well-controlled by methotrexate.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/immune-mediated-inflammatory-diseases-treatment-market
However, the late diagnosis of immune-mediated inflammatory disease coupled with challenges during the treatment such as slow or incomplete healing is limiting the growth of the global immune-mediated inflammatory disease treatment market. In addition, the high cost associated with the treatment also restricts the global immune-mediated inflammatory disease treatment market growth. For instance, due to their high costs, considerable differences in the utilization of treatment options exist across the globe. Various European countries are restricting access despite professional society guideline recommendations. Additionally, the adoption of biologic therapies for the treatment by healthcare providers has been particularly poor in many Central and Eastern European countries which are affecting the growth of immune-mediated inflammatory diseases. Moreover, the presence of a small patient base for rare disease coupled with disproportion in the availability of treatments and resources to manage patients, and train experts in developing economies will also limit the growth of the global immune-mediated inflammatory diseases treatment market.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/immune-mediated-inflammatory-diseases-treatment-market
Market Segmentation
By Disease Type
- Multiple Sclerosis
- Psoriasis
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
- Others
By Drug Class
- Anti- Inflammatory Biologics
- Non- Steroidal Anti- Inflammatory Drugs
- Corticosteroids
By Treatment Type
- Targeted Biologic Therapies
- Novel Therapies
Regional Analysis
North America
- US
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- Abbvie Inc.
- Abivax SA
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Celgene Corp.
- Daiichi Sankyo Co., Ltd.
- Eli Lilly and Co.
- Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
